Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Posted: December 17, 2020 at 7:55 am

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -

View original post here:
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Related Posts